58.39 0.00 (0.00%)
After hours: 6:44PM EST
|Bid||58.39 x 1400|
|Ask||58.60 x 800|
|Day's range||58.12 - 59.00|
|52-week range||42.48 - 59.00|
|Beta (3Y monthly)||0.69|
|PE ratio (TTM)||16.88|
|Earnings date||22 Jan 2020 - 27 Jan 2020|
|Forward dividend & yield||1.64 (2.82%)|
|1y target est||64.22|
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
Bristol-Myers' (BMY) label expansion application for Opdivo plus Yervoy combo regimen to include patients with hepatocellular carcinoma, a form of liver cancer, makes progress.
Bristol-Myers Squibb Company announced today the extension of the expiration date of the offers to exchange notes issued by Celgene Corporation for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company and cash and the related consent solicitations being made by Bristol-Myers Squibb on behalf of Celgene to adopt certain proposed amendments to the ...
Pfizer (PFE) and Merck KGaA's Bavencio misses the primary goal in a late-stage study evaluating it as the first-line maintenance therapy for patients with metastatic HER2-negative gastric cancer.
The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
Celgene (CELG) and partner Acceleron obtain FDA approval for Reblozyl for the treatment of anemia in adult patients with beta thalassemia.
The FDA also granted Opdivo plus Yervoy Breakthrough Therapy Designation for this potential indication
Novo Nordisk (NVO) and Allergan (AGN) release Q3 results. FDA approves Sanofi's quadrivalent flu vaccine for older adults and Novartis' long-acting biosimilar version of Amgen's Neulasta.
We wouldn't blame Bristol-Myers Squibb Company (NYSE:BMY) shareholders if they were a little worried about the fact...
Nektar's (NKTR) reports encouraging third-quarter results. The company continues to progress with its pipeline candidates. However, the timeline for its pain drug NKTR-181's approval remains uncertain.
Zacks.com featured highlights include: Group 1 Automotive, AbbVie, Brinker International, Hewlett Packard Enterprise and Bristol-Myers Squibb
PRINCETON, N.J.-- -- Remission maintenance and structural damage inhibition findings from the Phase IIIb AVERT-2 study highlight potential role for ORENCIA in de-escalation regimens in early moderate-to-severe rheumatoid arthritis patients positive for key biomarker for poor prognosis 1 Results from a U.S. national observational study demonstrate that anti-citrullinated protein autoantibodies -positive ...
Sustained sales growth is one of the most important characteristics of potential winners in the stock market. It provides investors an insight into product demand and pricing power.
The Zacks Analyst Blog Highlights: Group 1 Automotive, AbbVie, Brinker International, Hewlett Packard and Bristol-Myers Squibb
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.